AFT Pharmaceuticals Limited (ASX:AFP)

Market Cap	342.03M
Revenue (ttm)	207.12M
Net Income (ttm)	15.30M
Shares Out	n/a
EPS (ttm)	0.14
PE Ratio	22.36
Forward PE	23.67
Dividend	0.02 (0.55%)
Ex-Dividend Date	Jun 18, 2025

Volume	1,100
Average Volume	3,771
Open	3.190
Previous Close	3.060
Day's Range	3.190 - 3.190
52-Week Range	2.200 - 3.300
Beta	0.45
RSI	65.42
Earnings Date	Nov 19, 2025

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, dermatology, and hospital. It has a research and development collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injecta...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 119
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AFP

Financial Performance

In 2024, AFT Pharmaceuticals's revenue was 208.02 million, an increase of 6.45% compared to the previous year's 195.41 million. Earnings were 11.96 million, a decrease of -23.36%.

Financial numbers in NZD